Convalescent Plasma for Patients With COVID-19: A Randomized, Single Blinded, Parallel, Controlled Clinical Study

The process is based on obtaining plasma from patients recovered from COVID-19 in Colombia, and through a donation of plasma from the recovered, the subsequent transfusion of this to patients infected with coronavirus disease (COVID-19). Our group has reviewed the scientific evidence regarding the application of convalescent plasma for emergency viral outbreaks and has recommended the following protocol

Inclusion criteria

Fulfilling all the following criteria

• Olerder than 18.
• Hospitalized participants with diagnosis of COVID 19 by Real Time - Polymerase Chain Reaction.
• Severe cases according to the official guideline "Pneumonia Diagnosis and Treatment Scheme for Novel Coronavirus Infection (Trial Version 7)".
• Sequential Organ Failure Assessment score (SOFA) < 6.
• Ability to understand and the willingness to sign a written informed consent document.

Exclusion criteria

• Female subjects who are pregnant or breastfeeding.
• Patients with prior allergic reactions to transfusions.
• Critical ill patients in intensive care units with requierment of Invasive Mechanical Venitlation.
• Patients with surgical procedures in the last 30 days.
• Patients with active treatment for cancer (Radiotherapy or Chemotherapy).
• HIV diagnosed patients with viral failure (detectable viral load> 1000 copies / ml persistent, two consecutive viral load measurements within a 3 month interval, with medication adherence between measurements after at least 6 months of starting a new regimen antiretrovirals).
• Demonstrated coinfection that explains the patient's symptoms
• End-stage chronic kidney disease (Glomerular Filtration Rate <15 ml / min / 1.73 m2).
• Child Pugh C stage liver cirrhosis.
• High cardiac output diseases.
• Autoimmune diseases or Immunoglobulin A nephropathy.
• Patients have any condition that in the judgement of the Investigators would make the subject inappropriate for entry into this study.